Dapagliflozin ((2S)-1,2-propanediol, hydrate)

Dapagliflozin Propanediol Monohydrate is a sodium-glucose cotransporter 2 (SGLT-2) inhibitor, preventing glucose reabsorption in the kidney.

Product information

CAS Number: 960404-48-2

Molecular Weight: 502.98

Formula: C24H35ClO9

Synonym:

BMS-512148 (2S)-1,2-propanediol, hydrate

BMS512148 (2S)-1,2-propanediol, hydrate

BMS 512148 (2S)-1,2-propanediol, hydrate

Chemical Name: (2S)-propane-1,2-diol (2S,3R,4R,5S,6R)-2-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-6-(hydroxymethyl)oxane-3,4,5-triol hydrate

Smiles: O.C[C@H](O)CO.CCOC1C=CC(CC2=CC(=CC=C2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)=CC=1

InChiKey: GOADIQFWSVMMRJ-UPGAGZFNSA-N

InChi: InChI=1S/C21H25ClO6.C3H8O2.H2O/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21;1-3(5)2-4;/h3-8,10,17-21,23-26H,2,9,11H2,1H3;3-5H,2H2,1H3;1H2/t17-,18-,19+,20-,21+;3-;/m10./s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Dapagliflozin ((2S)-1, 2-propanediol, hydrate) (0-10 μM; 24 hours) significantly increases the cell survival in hypoxic HK2 cell in a dose-dependent manner. Dapagliflozin ((2S)-1, 2-propanediol, hydrate) (0-10 μM; 2 hours) increases the HIF1 expression, increases AMPK and EKR phosphorylation in hypoxic HK2 cells, but shows no effect on the phosphorylation of AMPK and ERK in normoxic HK2 cells.

In Vivo:

Dapagliflozin ((2S)-1, 2-propanediol, hydrate) is the S-enantiomer of Dapagliflozin 1, 2-propanediol, hydrate. Dapagliflozin ((2S)-1, 2-propanediol, hydrate), a new type of drug used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine. Dapagliflozin ((2S)-1, 2-propanediol, hydrate) induces HIF1 expression and attenuates renal IR injury.

References:

1. Vivian EM. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes. Am J Health Syst Pharm. 2015 Mar 1;72(5):361-72. doi: 10.2146/ajhp140168. Review. PubMed PMID: 25694411.
2. Liakos A, Karagiannis T, Bekiari E, Boura P, Tsapas A. Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab. 2015 Apr;6(2):61-7. doi: 10.1177/2042018814560735. Review. PubMed PMID: 25941564; PubMed Central PMCID: PMC4406879.

Products are for research use only. Not for human use.